Nov 25, 2019: Vaccitech Ltd, a clinical-stage T cell immunotherapy company develop the products for the treatment and prevention of cancer and infectious diseases, reports victorious recruitment and vaccination for its Universal influenza A vaccine MVA-NP+M1 (VTP-100), across two Phase 2 clinical studies, FLU009 and FLU010. Final data of FLU010 is expected in early 2020, the Phase 2 studies are part of a dual development pathway for VTP-100 that will deal with both pandemic and seasonal influenza vaccine markets.
FLU010 (randomised, double-blind, placebo controlled, influenza challenge) study conducted in Antwerp, Belgium, and co-funded by BARDA for $8.6M, 145 participants vaccinated, out of which 108 were challenged with the A/Belgium/4217/2015 (H3N2) influenza virus. Another group is programmed to be challenged by the end of this year. https://www.vaccitech.co.uk/vaccitech-provides-update-phase-2-influenza/
